Full Text View
Tabular View
No Study Results Posted
Related Studies
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
This study is currently recruiting participants.
Study NCT00330551   Information provided by National Institute of Mental Health (NIMH)
First Received: May 26, 2006   Last Updated: June 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Individual Case Management
Oral Risperidone
Additional drug interventions recognized in this trial
Risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
National Institute of Mental Health (NIMH)
Ortho-McNeil Janssen Scientific Affairs, LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services